Mylan is one of a group of drugmakers that have joined the global effort to supply doses of generic hydroxychloroquine, an antimalarial touted as a possible COVID-19 therapy, to ongoing clinical trials. Now, after ramping up production, Mylan is ready to dole out its stockpile faster than expected.
After announcing last month it would restart production of hydroxychloroquine to meet global demand, Mylan plans to donate millions of doses of the drug "ahead of schedule," the drugmaker said Wednesday.
Mylan will give away 10 million hydroxychloroquine tablets to the U.S. Department of Health and Human Services (HHS) to supplement investigational trials for COVID-19 and bolster the FDA's emergency use program.
In addition, Mylan's stockpile will help support the World Health Organization's (WHO) multi-arm Solidarity trial investigating a range of possible therapeutics for COVID-19, including hydroxychloroquine, Gilead Sciences' remdesivir and multiple combinations of HIV drugs lopinavir and ritonavir.
Mylan is the only drugmaker supplying 200-milligram doses of hydroxychloroquine for WHO testing and one of three donating supplies of lopinavir/ritonavir.
Mylan is also working with health officials to determine hydroxychloroquine's use as a prophylactic and identifying possible donation needs, the company said.